Recruiting

QuitVaping

Sponsor:

Massachusetts General Hospital

Code:

NCT06765291

Conditions

Vaping

Vaping Teens

Nicotine Dependence

Eligibility Criteria

Sex: All

Age: 14 - 19

Healthy Volunteers: Not accepted

Interventions

QuitVaping

This is Quitting (TIQ)

Study Details

Brief summary:

This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.

Conditions

Vaping

Vaping Teens

Nicotine Dependence

Study ID

NCT06765291

Start date

Jun 18, 2025

Status verified date

Jul, 2026

Completion date

Aug 31, 2029

Anticipated

Primary completion date

Feb 21, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 14 - 19

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 14-19 inclusive
  • Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months
  • Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO <10 ppm for those with an in person baseline visit
  • Report willingness to try to quit or reduce vaping in the next 30 days
  • Able to understand study procedures and read and write in English or Spanish
  • Have a parent or legal guardian who is able to participate in the opt out process
  • Competent and willing to provide written informed consent (if age 18) or assent (if under 18)

Exclusion Criteria:

  • Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
  • Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
  • Unwilling to provide saliva or urine samples
  • Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol

Study Design

Enrollment

400 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: QuitVaping (QV)

Participants will:

  • Attend QuitVaping behavioral support sessions, completed via videoconference or in-person, once per week for 12 weeks
  • Be encouraged to sign up for This is Quitting (TIQ), a text message vaping cessation program for adolescents

active comparator: Enhanced Usual Care (EUC)

Participants will:

  • Be encouraged to sign up for This is Quitting (TIQ), a text message vaping cessation program for adolescents
  • Attend no behavioral support sessions

Interventions

QuitVaping

QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.

This is Quitting (TIQ)

A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.

Primary outcome measure

  • Continuous 4-week nicotine vaping abstinence at end of treatment [ Time Frame: From week 9 to week 12 ]

Central Contacts and Locations

Central contacts

A. Eden Evins, MD, MPH

617-643-4679aeevins@mgh.harvard.edu

Julia Jashinski, MSW

617-643-1984jjashinski@mgh.harvard.edu

Locations

Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Julia Jashinski, MSW

617-643-1984jjashinski@mgh.harvard.edu

Principal Investigator:

A. Eden Evins, MD, MPH

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Jul 7, 2026

Last verified

Jul, 2026

Keywords

  • Vaping
  • Nicotine Depedence
  • Vaping Cessation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-07-07.